Document Status

This document has been corrected

Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors

10.1038/s41467-021-22362-2

Published Online: 2021-04-01

Journal: Nature Communications•Publisher: Springer Science and Business Media LLC

Authors: Alejandro Chavez•Arie Zask•Brent R. Stockwell•David D. Ho•Fang-Yu Lin•Farhad Forouhar•Hengrui Liu•Li Xing•Manoj S. Nair•Seo Jung Hong•Sho Iketani•Yaoxing Huang

This document has been corrected

Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors

10.1038/s41467-021-22362-2

Published Online: 2021-04-01

Journal: Nature Communications

Authors: Alejandro Chavez•Arie Zask•Brent R. Stockwell•David D. Ho•Fang-Yu Lin•Farhad Forouhar•Hengrui Liu•Li Xing•Manoj S. Nair•Seo Jung Hong•Sho Iketani•Yaoxing Huang

NOW

2021-05-05•Correction

Author Correction: Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors

10.1038/s41467-021-23082-3

* information provided by CrossRef

2021-05-05•Correction

10.1038/s41467-021-23082-3

* information provided by CrossRef

2021-04-01•Published